NCT06222580View on ClinicalTrials.gov

SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation

PHASE1RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

February 20, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Acute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 MutationRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia
Interventions
PROCEDURE

Biospecimen Collection

Undergo blood sample collection

PROCEDURE

Bone Marrow Aspiration and Biopsy

Undergo bone marrow aspiration and biopsy

DRUG

Gilteritinib

Given PO

DRUG

Revumenib

Given PO

Trial Locations (3)

19104

RECRUITING

University of Pennsylvania, Philadelphia

24514

RECRUITING

UNC Hospitals, University of North Carolina at Chapel Hill, Chapel Hill

43210

RECRUITING

Ohio State University Comprehensive Cancer Center, Columbus

All Listed Sponsors
lead

Uma Borate

OTHER